BioStock: Targinta’s CEO on TARG10 and the spin-off

Targinta has selected its first drug candidate TARG10, which shows an inhibitory effect on tumour growth and reduced metastasis in triple-negative breast cancer. In addition, the company is in an intensive phase where it is preparing for a spin-off from the parent company Xintela. BioStock contacted Targinta’s CEO Per Norlén to learn more about TARG10 and the spin-off. 

Read the interview with Targinta's CEO Per Norlén at biostock.se:

https://www.biostock.se/en/2021/10/targintas-ceo-on-targ10-and-the-spin-off/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se